Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442344 | 1.00 | KMT2A (0.51) | KMT2ALMNAHTTPKMHSD17B10 | |
| SCHEMBL5439050 | 1.00 | KMT2A (0.51) | KMT2ALMNAHTTPKMHSD17B10 | |
| SCHEMBL14183781 | 0.98 | KMT2A (0.49) | KMT2ALMNAHTTPKMHSD17B10 | |
| SCHEMBL6306635 | 0.95 | KMT2A (0.46) | KMT2ALMNAHTTPKMHSD17B10 | |
| SCHEMBL7111201 | 0.92 | ADORA3 (0.41) | KMT2ALMNAHTTPKMHSD17B10 | |
| SCHEMBL2953695 | 0.87 | ADORA3 (0.44) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4764723 | 0.87 | ADORA3 (0.44) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL29684584 | 0.87 | IKBKB (0.39) | KMT2AADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL16013820 | 0.85 | BTK (0.44) | KMT2ALMNAHTTADORA3ADORA1 | |
| SCHEMBL2948307 | 0.85 | CHEK1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-106456580-B | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | 科罗拉多州立大学董事会法人团体 | 2020-09-04 | — | — | CN | disclosed |
| US-RE47690-E1 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-11-05 | — | — | US | disclosed |
| US-RE47690-E1 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-11-05 | — | — | US | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-20180044352-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044352-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-02-15 | — | — | US | disclosed |
| US-9840520-B2 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840520-B2 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-12-12 | — | — | US | disclosed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| CN-101646669-A | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH AS DK | 2010-02-10 | — | — | CN | disclosed |
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-7544688-B2 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2009-06-09 | — | — | US | disclosed |
| WO-2008116909-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| EP-1537111-B1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| EP-1537111-A1 | HETEREOARYL NITRILE DERIVATIVES | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020441-A1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | KMT2A 3050/4885LMNA 599/4885HTT 3291/4885 |
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | TYMP, HPRT1, IMPDH1 | KMT2A 3845/4885LMNA 2248/4885HTT 4462/4885 |
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | CTSK, CTSS, CTSZ | KMT2A 3090/4885LMNA 3229/4885HTT 628/4885 |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | CTSK, CTSZ, CTSE | KMT2A 3089/4885LMNA 3123/4885HTT 107/4885 |
| US-20180044352-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | TTK, HDAC1, HDAC6 | KMT2A 720/4885LMNA 1716/4885HTT 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.